Misty Dawn Shields, Assistant professor of clinical medicine at Indiana University, shared on X:
“Grateful for the friendships, collaborations, and support of our amazing thoracic oncology community! Thankful to the amazing co-chairs Narjust Florez and Edward S. Kim for the kind invitation.
An honor to serve as the SCLC session lead where we discussed the unmet needs in our clinical practice, trials, and translational research that remain to be answered to best care for our Small Cell SMASHERS and their loved ones.
- How can we make the highest quality care accessible for all?
- With all of these new options, what is the best way to sequence our strategies?
- Importantly, how can we better support biomarker research to help expedite and identify WHO should get WHAT treatment?
We have made so much progress in the last 5 years! We must press on, work together, be creative, inquisitive, observant, persistent, and committed to never give up HOPE!”
You may also find this interesting:
Brain-Only Progression in ES-SCLC: When the Brain Progresses, the Systemic Backbone May Still Matter
